AML | Clinical

January 27, 2023

The latest patient enrolled in cohort 3 of the phase 1/2 MGTA-117 trial experienced a grade 5 serious adverse event resulting in death. The study has been halted to investigate the safety of the agent.

January 23, 2023

After the FDA cleared an investigational new drug application for mocravimod in April 2022, the first patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant have been enrolled in a phase 2b/3 study of the agent.

January 23, 2023

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

January 18, 2023

Updated guidelines recommend olutasidenib as a targeted therapy for patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

January 14, 2023

Rory Shallis, MD, discusses of the presence of the e-selectin molecule in the bone marrow and how it impacts the marrow microenvironment.

January 12, 2023

JBI-802, which is being evaluated in a phase 1/2 trial, received an orphan drug designation from the FDA for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

January 06, 2023

Eytan M. Stein, MD, discusses the unmet needs and challenges for treating patients with acute myeloid leukemia.

January 05, 2023

A phase 1/2 study of uproleselan combined with chemotherapy led to a complete response of 35% and median overall survival of 8.8 months in a cohort of patients with relapsed/refractory acute myeloid leukemia.

January 02, 2023

Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.

December 21, 2022

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.